Join to View Full Profile
1275 York AveNew York, NY 10065
Dr. Jeng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Mark Jeng, MD, is an oncology specialist based in New York, NY. He completed his residency in Internal Medicine at the University of California, San Francisco from 2020 to 2023, followed by a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center, running from 2023 to 2026. Dr. Jeng graduated from Stanford University School of Medicine in 2020 and holds a PhD in Biomedical Sciences: Immunology from UCSF, completed in 2016. His research is well-documented, with publications in leading journals such as the Journal of Clinical Oncology and the American Journal of Hematology. His work has explored topics like novel therapies for leukemia and Pembrolizumab for basal cell carcinoma, with multiple citations highlighting the impact of his research.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2023 - 2026
University of California (San Francisco)Residency, Internal Medicine, 2020 - 2023
Stanford University School of MedicineClass of 2020
UCSFPhD, Biomedical Sciences: Immunology, 2011 - 2016
Certifications & Licensure
NY State Medical License 2023 - 2027
CA State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell ...Federica Pecci, Rohit Thummalapalli, Stephanie L Alden, Biagio Ricciuti, Joao V Alessi
Clinical Cancer Research. 2025-06-13 - 1 citationsOutcomes After Radiation for Oligoprogressive Disease Sites in Patients With-Mutant Lung Cancer Treated With Osimertinib.Monica F Chen, Mark Y Jeng, Jennifer Ma, Prashasti Agrawal, Elizabeth Dunne
JCO Precision Oncology. 2025-05-01 - Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.Mark Y Jeng, Adam J Schoenfeld
Clinical Cancer Research. 2025-04-14
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
